Guardant Health (GH) secured a major win as CMS approved Advanced Diagnostic Laboratory Test (ADLT) status for its Shield blood test for colorectal cancer (CRC) screening, enabling Medicare reimbursement at $1,495 starting April 1, 2025—up from the previously assumed $920. Analysts, including William Blair’s Andrew Brackmann, view this as a significant positive, estimating it could add approximately $10 million in revenue, with further potential upside if adoption scales.
Keep Reading
Add A Comment